https://scholars.lib.ntu.edu.tw/handle/123456789/631868
標題: | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis | 作者: | Sunami, Kazutaka Ikeda, Takashi SHANG-YI HUANG Wang, Ming-Chung Koh, Youngil Min, Chang Ki Yeh, Su-Peng Matsumoto, Morio Uchiyama, Michihiro Iyama, Satoshi Shimazaki, Chihiro Lee, Jae Hoon Kim, Kihyun Kaneko, Hitomi Kim, Jin Seok Lin, Tung-Liang Campana, Frank Tada, Keisuke Iida, Shinsuke Suzuki, Kenshi |
關鍵字: | Efficacy and safety; Far East; Isa-Pd; Japan; RRMM | 公開日期: | 八月-2022 | 出版社: | CIG MEDIA GROUP, LP | 卷: | 22 | 期: | 8 | 起(迄)頁: | E751 | 來源出版物: | Clinical lymphoma, myeloma & leukemia | 摘要: | In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/631868 | ISSN: | 2152-2650 | DOI: | 10.1016/j.clml.2022.04.005 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。